COVID-19’un Enflamatuvar Bağırsak Hastalarındaki Sonuçları: Üçüncü Basamak Merkez Deneyimi

Batuhan BAŞPINAR; İbrahim Ethem GÜVEN; İlhami YÜKSEL

doi:10.4274/mjima.galenos.2022.2021.25

COVID-19’un Enflamatuvar Bağırsak Hastalarındaki Sonuçları: Üçüncü Basamak Merkez Deneyimi

PDF

ÖZGÜN MAKALE

COVID-19’un Enflamatuvar Bağırsak Hastalarındaki Sonuçları: Üçüncü Basamak Merkez Deneyimi

Mediterr J Infect Microb Antimicrob 2022;11:25-25 DOI: 10.4274/mjima.galenos.2022.2021.25

, ,

PDF

İzin

Öz

Giriş: Şiddetli akut solunum yolu sendromu-Koronavirüs-2 (SARS-CoV-2) enfeksiyonunun enflamatuvar bağırsak hastalığında (İBH) sıklığı, risk faktörleri ve sonucu hala belirsizliğini korumaktadır. Bu çalışma, İBH’de SARS-CoV-2 enfeksiyonunun insidansını ve etkilerini araştırmayı amaçlamaktadır.

Gereç ve Yöntem: İBH hastaları Mart 2020 ile Mart 2021 arasında geriye dönük olarak dahil edildi. SARS-CoV-2 enfeksiyonu olan hastalar analiz edildi.

Bulgular: Çalışma süresinde 894 İBH hastası başvurdu. SARS-CoV-2, 18 (%2,0) hastada tespit edildi: Crohn hastalığı (CH) olan 430 hastanın beşi (%1,2), ülseratif kolit (ÜK) olan 428 hastanın 12’si (%2,8) ve 36 sınıflandırılmamış-İBH (İBH-U) olan hastanın birinde (%2,8) ortalama yaş 42,2 yıldı. Hastaların 12’si (%66,7) erkekti. Hastaların hiçbirinde Koronavirüs hastalığı-2019’a karşı aşılanma öyküsü yoktu. Beş (%27,8) hasta ortanca 10 gün hastanede yattı, geri kalan hastalar evde izole edildi. Yoğun bakım ünitesine yatış veya ölüm olmadı. Hastalık alevlenmesi gözlenmemesine rağmen, steroid kullanan ÜK’li bir hastada geçici terminal ileit, pnömonitis intestinalis ve rekto-vajinal fistül görüldü. Altı (%33,3) hasta biyolojik ajan kullanıyordu ve bir hastada eş zamanlı immünomodülatör ve steroid tedavisi vardı. Başlıca gastrointestinal (Gİ) semptom altı (%33,3) hastada ishaldi.

Sonuç: İBH hastalarında SARS-CoV-2 enfeksiyonunun insidansı %2.0 (n=18) bulunmuş olup ishal en sık görülen Gİ semptomdur ve hastalık alevlenmesi ile karıştırılmamalıdır.

Anahtar Kelimeler: COVID-19, Crohn hastalığı, enflamatuvar bağırsak hastalığı, SARS-CoV-2, ülseratif kolit

Kaynakça

1

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-20.

2

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475-81.

3

Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2020;52:276-83.

4

Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020;323:1775-6.

5

Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621.

6

Wisniewski A, Kirchgesner J, Seksik P, Landman C, Bourrier A, Nion-Larmurier I, Marteau P, Cosnes J, Sokol H, Beaugerie L; the Saint-Antoine IBD network. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. United European Gastroenterol J. 2019;8:303-13.

7

Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD. Crohn’s Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. Am J Gastroenterol. 2016;111:1806-15.

8

Attauabi M, Poulsen A, Theede K, Pedersen N, Larsen L, Jess T, Rosager Hansen M, Verner-Andersen MK, V Haderslev K, Berg Lødrup A, Molazahi A, Neumann A, Wase A, Seidelin JB, Burisch J. Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study. J Crohns Colitis. 2021;15: 540-50.

9

Aziz M, Fatima R, Haghbin H, Lee-Smith W, Nawras A. The Incidence and Outcomes of COVID-19 in IBD Patients: A Rapid Review and Meta-analysis. Inflammatory Bowel Dis. 2020; 26:132-3.

10

Derikx LAAP, Lantinga MA, de Jong DJ, van Dop WA, Creemers RH, Römkens TEH, Jansen JM, Mahmmod N, West RL, Tan ACITL, Bodelier AGL, Gorter MHP, Boekema PJ, Halet ERC, Horjus CS, van Dijk MA, Hirdes MMC, Epping Stippel LSM, Jharap B, Lutgens MWMD, Russel MG, Gilissen LPL, Nauta S, van Bodegraven AA, Hoentjen F. Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study. J Crohns Colitis. 2021;15:529-39.

11

Singh S, Khan A, Chowdhry M, Bilal M, Kochhar GS, Clarke K. Risk of Severe Coronavirus Disease 2019 in Patients With Inflammatory Bowel Disease in the United States: A Multicenter Research Network Study. Gastroenterology. 2020;159:1575-8.

12

Axelrad JE, Malter L, Hong S, Chang S, Bosworth B, Hudesman D. From the American Epicenter: Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease in the New York City Metropolitan Area. Inflamm Bowel Dis. 2021;27:662-6.

13

Allocca M, Fiorino G, Zallot C, Furfaro F, Gilardi D, Radice S, Danese S, Peyrin-Biroulet L. Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. Clin Gastroenterol Hepatol. 2020;18:2134-2135.

14

Gubatan J, Levitte S, Balabanis T, Patel A, Sharma A, Habtezion A. SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California. Gastroenterology. 2020;159:1141-4.

15

Khan N, Patel D, Xie D, Pernes T, Lewis J, Yang YX. Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans’ Affairs Cohort Study. Am J Gastroenterol. 2021;116:808-10.

16

Anikhindi SA, Kumar A, Arora A. COVID-19 in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2020;14:1187-93.

17

Lukin DJ, Kumar A, Hajifathalian K, Sharaiha RZ, Scherl EJ, Longman RS; Jill Roberts Center Study Group Study Group; Weill Cornell Medicine-Gastrointestinal Study Group. Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease. Gastroenterology. 2020;159:1541-4.

18

Mao R, Liang J, Shen J, Ghosh S, Zhu LR, Yang H, Wu KC, Chen MH; Chinese Society of IBD, Chinese Elite IBD Union; Chinese IBD Quality Care Evaluation Center Committee. Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol. 2020;5:425-7.

19

Norsa L, Indriolo A, Sansotta N, Cosimo P, Greco S, D’Antiga L. Uneventful Course in Patients With Inflammatory Bowel Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak in Northern Italy. Gastroenterology. 2020;159:371-2.

20

Rodríguez-Lago I, Ramírez de la Piscina P, Elorza A, Merino O, Ortiz de Zárate J, Cabriada JL. Characteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basque Country (Spain). Gastroenterology. 2020;159:781-3.

21

Ludvigsson JF, Axelrad J, Halfvarson J, Khalili H, Larsson E, Lochhead P, Roelstraete B, Simon TG, Söderling J, Olén O. Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden. United European Gastroenterol J. 2021;9: 177-92.

22

Luo S, Zhang X, Xu H. Don’t Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19). Clin Gastroenterol Hepatol. 2020;18:1636-7.

23

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.

24

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13.

25

Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, Wang HY, Zhang S, Gao HN, Sheng JF, Cai HL, Qiu YQ, Li LJ. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368: m606.

26

Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, Shen J, Zhu LR, Chen Y, Iacucci M, Ng SC, Ghosh S, Chen MH. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:667-78.

27

Elmunzer BJ, Spitzer RL, Foster LD, Merchant AA, Howard EF, Patel VA, West MK, Qayed E, Nustas R, Zakaria A, Piper MS, Taylor JR, Jaza L, Forbes N, Chau M, Lara LF, Papachristou GI, Volk ML, Hilson LG, Zhou S, Kushnir VM, Lenyo AM, McLeod CG, Amin S, Kuftinec GN, Yadav D, Fox C, Kolb JM, Pawa S, Pawa R, Canakis A, Huang C, Jamil LH, Aneese AM, Glamour BK, Smith ZL, Hanley KA, Wood J, Patel HK, Shah JN, Agarunov E, Sethi A, Fogel EL, McNulty G, Haseeb A, Trieu JA, Dixon RE, Yang JY, Mendelsohn RB, Calo D, Aroniadis OC, LaComb JF, Scheiman JM, Sauer BG, Dang DT, Piraka CR, Shah ED, Pohl H, Tierney WM, Mitchell S, Condon A, Lenhart A, Dua KS, Kanagala VS, Kamal A, Singh VK, Pinto-Sanchez MI, Hutchinson JM, Kwon RS, Korsnes SJ, Singh H, Solati Z, Willingham FF, Yachimski PS, Conwell DL, Mosier E, Azab M, Patel A, Buxbaum J, Wani S, Chak A, Hosmer AE, Keswani RN, DiMaio CJ, Bronze MS, Muthusamy R, Canto MI, Gjeorgjievski VM, Imam Z, Odish F, Edhi AI, Orosey M, Tiwari A, Patwardhan S, Brown NG, Patel AA, Ordiah CO, Sloan IP, Cruz L, Koza CL, Okafor U, Hollander T, Furey N, Reykhart O, Zbib NH, Damianos JA, Esteban J, Hajidiacos N, Saul M, Mays M, Anderson G, Wood K, Mathews L, Diakova G, Caisse M, Wakefield L, Nitchie H, Waljee AK, Tang W, Zhang Y, Zhu J, Deshpande AR, Rockey DC, Alford TB, Durkalski V; North American Alliance for the Study of Digestive Manifestations of COVID-19. Digestive Manifestations in Patients Hospitalized With Coronavirus Disease 2019. Clin Gastroenterol Hepatol. 2021;19:1355-65.

28

Song Y, Liu P, Shi XL, Chu YL, Zhang J, Xia J, Gao XZ, Qu T, Wang MY. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut. 2020;69:1143-4.

29

Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020;323:1843-4.

30

Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020;158:1831-3.

31

Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X, Yin H, Xiao Q, Tang Y, Qu X, Kuang L, Fang X, Mishra N, Lu J, Shan H, Jiang G, Huang X. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. 2020;5:434-35.

32

Gupta S, Kaushik A, Kest H, Charles AK, De Bruin W, Colletti M, Goldberg D. Severe Enteritis as the Sole Manifestation of Novel Coronavirus Disease 2019 (COVID-19) in Adolescent Patients. Case Rep Infect Dis. 2020;2020:8823622.

33

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, Shen C, Li X, Peng L, Huang D, Zhang J, Zhang S, Wang F, Liu J, Chen L, Chen S, Wang Z, Zhang Z, Cao R, Zhong W, Liu Y, Liu L. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020;6:1192-8.

34

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323:1824-36.

35

Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, Gordeev IG, Ilin AP, Karapetian RN, Kravchenko DV, Lomakin NV, Merkulova EA, Papazova NA, Pavlikova EP, Savchuk NP, Simakina EN, Sitdekov TA, Smolyarchuk EA, Tikhomolova EG, Yakubova EV, Ivachtchenko AV. AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis. 2021;73:531-4.

36

Maslennikov R, Poluektova E, Ivashkin V, Svistunov A. Diarrhoea in adults with coronavirus disease-beyond incidence and mortality: a systematic review and meta-analysis. Infect Dis (Lond). 2021;53:348-60.

37

Marafini I, Salvatori S, Sena G, Calabrese E, Biancone L, Monteleone G. Low frequency of COVID-19 in inflammatory bowel diseases. Dig Liver Dis. 2020;52:1234-5.

38

Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020;159:481-91.

39

Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2018;155:337-46.

40

Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413.

41

Bhayana R, Som A, Li MD, Carey DE, Anderson MA, Blake MA, Catalano O, Gee MS, Hahn PF, Harisinghani M, Kilcoyne A, Lee SI, Mojtahed A, Pandharipande PV, Pierce TT, Rosman DA, Saini S, Samir AE, Simeone JF, Gervais DA, Velmahos G, Misdraji J, Kambadakone A. Abdominal Imaging Findings in COVID-19: Preliminary Observations. Radiology. 2020;297:207-15.

42

Santana GO, de Santana AC, Pfeilsticker VB. Ileum Perforation in Crohn’s Disease Patient During SARS-Cov-2 Infection. Inflamm Bowel Dis. 2021;27:e42.